Results 11 to 20 of about 82,941 (302)

The Landscape of Targeted Therapies in TNBC

Cancers, 2020
Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen months.
Vagia, Elena, Mahalingam, Devalingam, Cristofanilli, Massimo   +2 more
openaire   +2 more sources

Clinical Significance of the Transcription Factor SOX11, Cell-Cell Adhesion Protein E-cadherin and Zinc Finger Protein BCL11A in the Diagnosis of Breast Cancer

Archives of Pharmaceutical Sciences Ain Shams University, 2021
Transcription factors (TFs) as SRY-Box transcription factor 11 (SOX11) and B-cell lymphoma/leukemia 11A (BCL11A) role in breast cancer (BC) as well as their effect on epithelial cadherin (E-cadherin) membrane protein which is a metastasis suppressor is a
Salma Salama, Nadia Hamdy, Reham El-Shimy, Hala El-Mesallamy   +3 more
doaj   +1 more source

NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. [PDF]

, 2018
Notch dysregulation has been implicated in numerous tumors, including triple-negative breast cancer (TNBC), which is the breast cancer subtype with the worst clinical outcome.
Bellavia, Diana, Besharat, ZEIN MERSINI, Capalbo, Carlo, Checquolo, Saula, D'Amati, Giulia, Del Gaudio, Francesca, Diluvio, Giulia, Franciosa, Giulia, Giuli, MARIA VALERIA, Giuliani, Eugenia, Maroder, Marella, Palermo, Rocco, Pignataro, MARIA GEMMA, Talora, Claudio, Vacca, Alessandra   +14 more
core   +2 more sources

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures [PDF]

, 2011
Background: Current prognostic gene signatures for breast cancer mainly reflect proliferation status and have limited value in triple-negative (TNBC) cancers.
Karn, Thomas, Pusztai, Lajos, Holtrich, Uwe, Iwamoto, Takayuki, Shiang, Christine Y., Schmidt, Marcus, Müller, Volkmar, Solbach, Christine, Gätje, Regine, Hanker, Lars, Ahr, André, Liedtke, Cornelia, Ruckhäberle, Eugen, Kaufmann, Manfred, Rody, Achim   +14 more
core   +1 more source

Robust Identification of Target Genes and Outliers in Triple-negative Breast Cancer Data [PDF]

, 2018
Correct classification of breast cancer sub-types is of high importance as it directly affects the therapeutic options. We focus on triple-negative breast cancer (TNBC) which has the worst prognosis among breast cancer types.
Casimiro, Sandra, Lopes, Marta B., Rousseeuw, Peter J., Segaert, Pieter, Vinga, Susana   +4 more
core   +2 more sources

Cripto-1 in TNBC

Aging, 2015
Among all breast cancer molecular subtypes, triple-negative breast cancer (TNBC) presents the poorest prognosis due to the lack of effective therapeutic options. TNBC, characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or HER-2 genes, represents approximately 10%–20% of invasive breast cancers and has been ...
Nadia P, Castro, David S, Salomon
openaire   +2 more sources

Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model

OncoImmunology, 2020
Triple-negative breast cancer is the most aggressive subtype of breast cancer and is difficult to treat. Breast cancer is considered to be poorly immunogenic and hence is less responsive to immunotherapies.
Shyambabu Chaurasiya, Annie Yang, Seonah Kang, Jianming Lu, Sang-In Kim, Anthony K. Park, Venkatesh Sivanandam, Zhifang Zhang, Yanghee Woo, Susanne G. Warner, Yuman Fong   +10 more
doaj   +1 more source

Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo [PDF]

, 2016
Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer. Lacking effective therapeutic options hinders treatment of TNBC. Here, we show that bepridil (BPD) and trifluoperazine (TFP), which are FDA-approved drugs for treatment of ...
Berek, Jonathan S, Chung, Young Min, Hu, Mickey C-T, Ma, Jessica, Park, See-Hyoung, Yang, Qin   +5 more
core   +2 more sources

Chemotherapy with ceramide in TNBC

Oncoscience, 2015
Metastasis remains the major cause of cancer-related mortality, and currently there is a lack of therapies to eliminate this risk. Therefore, it is of crucial interest to better understand this multi-step cellular process and find the best markers to identify patients who will develop early and distant relapse.
Legembre, Patrick, Micheau, Olivier, Ségui, Bruno   +2 more
openaire   +3 more sources

The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. [PDF]

, 2016
Basal-like breast cancers (BLBCs) are aggressive breast cancers associated with poor survival. Defining the key drivers of BLBC growth will allow identification of molecules for targeted therapy.
Brown, Powel H, Hilsenbeck, Susan G, Mazumdar, Abhijit, Savage, Michelle, Shepherd, Jonathan H, Tsimelzon, Anna, Uray, Ivan P   +6 more
core   +5 more sources